EP Patent

EP2540349A1 — Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitor

Assigned to MSD Italia SRL · Expires 2013-01-02 · 13y expired

What this patent protects

The present invention relates to a macrocyclic compound of formula ( I ) useful as an inhibitor of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections, in solid pharmaceutical compositions suitable for oral administration.

USPTO Abstract

The present invention relates to a macrocyclic compound of formula ( I ) useful as an inhibitor of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections, in solid pharmaceutical compositions suitable for oral administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP2540349A1
Jurisdiction
EP
Classification
—
Expires
2013-01-02
Drug substance claim
No
Drug product claim
No
Assignee
MSD Italia SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.